CD274 and renal cell carcinoma: Thirty-nine out of 184 gastric and gastroesophageal carcinoma patients reported IRR (21.2 %, 95 % CI 15.5%–27.8 %), and eighty-seven renal cell carcinoma patients experienced treatment-related diarrhea (22.3 %, 95 % CI 18,3%–26.8 %) after PD-L1 inhibitor treatment.